Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 0%
- Matching filter
- 4
F·Filter
Reset allT3·Expert-primary work
Domain-expert primary sources outside the journal pipeline — lectures, podcasts, position papers.
4 sources
- 2026Cohortmoderate
Semaglutide is associated with improved breast cancer survival, lower metastatic burden, and a dose-survival relationship uncoupled from weight-loss magnitude
Murugadoss K, Venkatakrishnan AJ, Soundararajan V · medRxiv (preprint)
In a federated EHR network of nearly 29 million patients with 1:1 propensity-matched pooled-comparator analyses, semaglutide-treated breast cancer patients had 54 deaths/2,433 (2.2%) versus 395 deaths/2,433 (16.2%) in metformin/SGLT2i/DPP4i comparators over 24 months (log-rank P<0.001); high-dose semaglutide (≥1.7 mg) had ~1.0% event rate vs ~4.5% in low-dose (0.25–1.0 mg, P=0.034), while weight-loss strata did not separate survival (P=0.22) — and any-metastasis incidence was 7.0% vs 15.0% (rate ratio 0.5, P<0.001).
- 2026Reviewmoderate
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review
Pillai AA, Godin SL, Frishman WH, +1 · Cardiology in Review
A cardiology-group synthesis of retatrutide's Phase 2 data: 12 mg weekly drives 24.2% body-weight reduction at 48 weeks with 63% achieving ≥20% loss, 2.02% HbA1c reduction with 27% reaching normoglycemia, and 82.4% relative reduction in hepatic fat — alongside an 8.79 mm Hg systolic-pressure drop and a chronotropic safety signal worth monitoring.
- 2026Meta-analysismoderaten=63,909
A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: 2026 Update
Ciudin Mihai A, Baker JL, Belancic A, +3 · medRxiv (preprint)
A network meta-analysis pooling 66 RCTs and 63,909 patients across six obesity management medication classes finds tirzepatide and semaglutide as the only compounds exceeding 10% total body weight loss, with semaglutide reducing MACE and all-cause mortality, both incretins benefiting heart-failure outcomes and MASH remission, tirzepatide improving obstructive sleep apnoea, semaglutide improving knee osteoarthritis pain remission and liver fibrosis — and no OMM associated with increased serious adverse events.
- 2006Reviewmoderate
Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Kovalzon VM, Strekalova TV · Journal of Neurochemistry
Russian sleep researchers Kovalzon and Strekalova argue that after three decades of work, the 'DSIP is a sleep factor' hypothesis remains weakly documented — no receptor identified, no gene confirmed, no consistent acute sleep-induction effect in standardised paradigms. The most rigorous published skepticism toward the foundational DSIP claim.